• This record comes from PubMed

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study

. 2018 Sep ; 37 (9) : 2331-2340. [epub] 20180425

Language English Country Germany Media print-electronic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/pmid29696436
Links

PubMed 29696436
DOI 10.1007/s10067-018-4113-3
PII: 10.1007/s10067-018-4113-3
Knihovny.cz E-resources

To compare the prevalence of cardiovascular disease (CVD) and major CVD risk factors among rheumatoid arthritis (RA) patients enrolled in a large US and multinational registry. We compared CVD and CVD risk factor prevalence from 11 countries enrolled in the CORRONA US and CORRONA International registries; patients from the 10 ex-US participating countries were grouped by region (Eastern Europe, Latin America, and India). Unadjusted summary data were presented for demographics and disease characteristics; comparisons for prevalence of CVD risk factors and CVD were age/gender standardized to the age/gender distribution of the US enrolled patients. Overall, 25,987 patients were included in this analysis. Compared to patients from the ex-US regions, US participants had longer disease duration and lower disease activity, yet were more likely to receive a biologic agent. Additionally, CORRONA US participants had the highest body mass index (BMI). Enrolled patients in India had the lowest BMI, were more rarely smokers, and had a low prevalence of hyperlipidemia, hypertension, and prior CVD compared to the US and other ex-US regions. Participants from Eastern Europe had a higher prevalence of hypertension and hyperlipidemia and highest prevalence of all manifestations of CVD. Differences in the prevalence of both CVD and major CVD risk factors were observed across the four regions investigated. Observed differences may be influenced by variations in both non-modifiable/modifiable characteristics of patient populations, and may contribute to heterogeneity on the observed safety of investigational and approved therapies in studies involving RA patients from different origins.

See more in PubMed

Autoimmun Rev. 2006 Jan;5(1):46-54 PubMed

Am J Med. 2008 Oct;121(10 Suppl 1):S9-14 PubMed

Arthritis Rheum. 2007 Nov;56(11):3583-7 PubMed

J Rheumatol. 1999 Dec;26(12):2562-71 PubMed

J Rheumatol. 2004 Sep;31(9):1823-8 PubMed

Circulation. 2005 Sep 13;112(11):1651-62 PubMed

Arthritis Rheum. 2009 Nov 15;61(11):1571-9 PubMed

Rheumatology (Oxford). 2007 Feb;46(2):350-7 PubMed

PLoS One. 2013;8(1):e54056 PubMed

Scand J Rheumatol. 2000;29(1):29-37 PubMed

Arthritis Rheum. 2005 Feb;52(2):402-11 PubMed

Clin Rheumatol. 2001;20(2):123-7 PubMed

J Rheumatol. 1999 Dec;26(12):2529-33 PubMed

Arthritis Rheum. 2005 Mar;52(3):722-32 PubMed

Arthritis Rheum. 2005 Oct;52(10):3039-44 PubMed

Arthritis Rheum. 2008 Aug;58(8):2268-74 PubMed

Arthritis Rheum. 1994 Apr;37(4):481-94 PubMed

Heart. 2008 Jan;94(1):16-26 PubMed

Arthritis Rheum. 1994 Aug;37(8):1158-65 PubMed

Arthritis Rheum. 2002 Mar;46(3):625-31 PubMed

Arthritis Res Ther. 2009;11(3):229 PubMed

Indian J Med Res. 2006 Sep;124(3):235-44 PubMed

Arthritis Rheum. 2000 Jan;43(1):14-21 PubMed

Arthritis Rheum. 2008 Sep;58(9):2603-11 PubMed

Arthritis Res Ther. 2011 Aug 15;13(4):R131 PubMed

Arthritis Rheum. 2001 Jun;44(6):1467-9 PubMed

Find record

Citation metrics

Archiving options